Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824329 · ClinicalTrials.gov registry record · Phase 2
Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01824329 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 40 participants.
The verdict
NCT01824329, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Bladder cancer is the 4th most common cancer amongst men. If bladder cancer invades the muscle of the bladder or fails local treatments, surgical removal of the bladder (cystectomy) with creation of a new bladder from intestine is required. However, standard cystectomy affects urinary function and sexual function. The investigators are evaluating two modifications to cystectomy to determine to what extent they preserve urinary and sexual function.
Interventions
- PROCEDURE Prostate capsule sparing cystectomy
- PROCEDURE Nerve sparing cystectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-06 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01824329
The ClinicalTrials.gov registry entry for NCT01824329 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prostate capsule sparing cystectomy is the first listed.
NCT01824329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01824329 about?
NCT01824329 is a clinical study titled "Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer". Bladder cancer is the 4th most common cancer amongst men. If bladder cancer invades the muscle of the bladder or fails local treatments, surgical removal of the bladder (cystectomy) with creation of a new bladder from intestine is required. However, standard cystectomy affects urinary function and s...
What is the current status of trial NCT01824329?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-06. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01824329?
The interventions under investigation include: Prostate capsule sparing cystectomy (PROCEDURE), Nerve sparing cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT01824329?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.